Syndax Pharmaceuticals, Inc. (SNDX)
19.57
-0.08
(-0.41%)
USD |
NASDAQ |
Aug 24, 16:00
19.70
+0.13
(+0.66%)
After-Hours: 20:00
Syndax Pharmaceuticals Profit Margin (Quarterly) : -67.82% for June 30, 2026
Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -67.82% |
| March 31, 2026 | -65.79% |
| December 31, 2025 | -98.96% |
| September 30, 2025 | -132.4% |
| June 30, 2025 | -189.3% |
| March 31, 2025 | -423.3% |
| December 31, 2024 | -1.23K% |
| September 30, 2024 | -673.0% |
| June 30, 2024 | -1.94K% |
| March 31, 2024 | |
| December 31, 2023 | |
| September 30, 2023 | |
| June 30, 2023 | |
| March 31, 2023 | |
| December 31, 2022 | |
| September 30, 2022 | |
| June 30, 2022 | |
| March 31, 2022 | |
| December 31, 2021 | 76.00% |
| September 30, 2021 | -166.8% |
| June 30, 2021 | -6.04K% |
| Date | Value |
|---|---|
| March 31, 2021 | -7.31K% |
| December 31, 2020 | -5.37K% |
| September 30, 2020 | -5.39K% |
| June 30, 2020 | -4.50K% |
| March 31, 2020 | -5.05K% |
| December 31, 2019 | -3.68K% |
| September 30, 2019 | -3.38K% |
| June 30, 2019 | -3.94K% |
| March 31, 2019 | -3.77K% |
| December 31, 2018 | -4.96K% |
| September 30, 2018 | -4.57K% |
| June 30, 2018 | -4.85K% |
| March 31, 2018 | -5.12K% |
| December 31, 2017 | -1.60K% |
| September 30, 2017 | -4.95K% |
| June 30, 2017 | -4.47K% |
| March 31, 2017 | -4.25K% |
| December 31, 2016 | -3.55K% |
| September 30, 2016 | -4.91K% |
| June 30, 2016 | -2.74K% |
| March 31, 2016 | -3.39K% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Profit Margin (Quarterly) Benchmarks
| Viking Therapeutics, Inc. | -- |
| Kura Oncology, Inc. | -327.3% |
| ACADIA Pharmaceuticals, Inc. | 10.23% |
| Alnylam Pharmaceuticals, Inc. | 12.74% |
| Anika Therapeutics, Inc. | 10.15% |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -280.0% |
| Return on Assets | -38.68% |
| Return on Invested Capital | -46.67% |
| Gross Profit Margin (Quarterly) | 95.59% |
| Operating Margin (Quarterly) | -54.95% |
| Return on Net Operating Assets | -253.5% |